Vancouver, Canada, July 15, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the expansion of its Phase I/IIa clinical trial for CMND-100, its proprietary MEAI-based oral treatment candidate for Alcohol Use Disorder (AUD), with the activation of additional site at Johns Hopkins ...

Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a propri ...

Vancouver, Canada, June 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced a historic milestone: the first participant has been dosed with CMND-100, its proprietary MEAI-based oral drug candidate, in its Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder (AU ...

Vancouver, Canada, June 27, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the addition of Hadassah-University Medical Center, Jerusalem, Israel, as a new clinical site for its ongoing Phase I/IIa clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidat ...

Core Insights - Clearmind Medicine Inc. has initiated a Phase I/IIa clinical trial for CMND-100, a proprietary MEAI-based oral drug candidate aimed at treating Alcohol Use Disorder (AUD), which affects hundreds of millions globally [1][2] - The trial's primary focus is on evaluating the safety, tolerability, and pharmacokinetic profile of CMND-100, with preliminary efficacy assessments to determine its potential in reducing alcohol cravings and consumption [2] Company Overview - Clearmind is a clinical-stage biotech company dedicated to developing novel psychedelic-derived therapeutics to address significant health issues, including AUD [4] - The company has a robust intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5] Market Potential - The substance use disorder treatment market in the U.S. was valued at $35.1 billion in 2021 and is projected to grow to $60.2 billion by 2029, indicating a significant opportunity for innovative treatments like CMND-100 [3]

Core Insights - Clearmind Medicine Inc. is advancing its mission to develop psychedelic-derived therapeutics by engaging a prominent government and political affairs consulting firm to navigate regulatory landscapes and promote acceptance among U.S. policymakers [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on discovering and developing novel psychedelic-derived therapeutics aimed at addressing major under-treated health issues, including alcohol use disorder [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property as opportunities arise [5] Industry Context - The pharmaceutical industry is increasingly recognizing the potential of psychedelics to treat conditions such as Post-Traumatic Stress Disorder (PTSD) and other mental health disorders, necessitating informed regulatory frameworks to facilitate the integration of these therapies into mainstream healthcare [2][3] - Clearmind's lead candidate, CMND-100, is currently undergoing Phase I/IIa clinical trials for alcohol use disorder at prestigious institutions, including Yale School of Medicine and Johns Hopkins University [3]

Vancouver, Canada, June 23, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the addition of Tel Aviv Sourasky Medical Center (TASMC), Tel Aviv, Israel, as an additional clinical site for its ongoing Phase I/IIa clinical trial evaluating CMND-100, a proprietary MEAI-based oral ...

Exhibit 99.1 CLEARMIND MEDICINE INC. Condensed Interim Consolidated Financial Statements For The Three and Six Months Ended April 30, 2025 (Expressed in United States Dollars) (Unaudited) CLEARMIND MEDICINE INC. Condensed Interim Consolidated Statements of Financial Position (Expressed in United States Dollars) (Unaudited) | | April 30, | | October 31, | | --- | --- | --- | --- | | | 2025 | | 2024 | | Assets | | | | | Current assets | | | | | Cash and cash equivalents | $ 4,472,520 | | $ 6,573,813 | | Other ...

Core Insights - Clearmind Medicine Inc. has engaged a leading government and political affairs consulting firm to advance its mission of developing psychedelic-based therapeutics [1][2] - The company aims to navigate complex regulatory landscapes and promote acceptance of psychedelic therapies among U.S. policymakers [2][3] - Clearmind's lead candidate, CMND-100, is currently in Phase I/IIa clinical trials for alcohol use disorder (AUD) at prestigious institutions [3] Company Overview - Clearmind is a clinical-stage biotech company focused on discovering and developing psychedelic-derived therapeutics to address under-treated health issues, including AUD [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as needed [5] Industry Context - The pharmaceutical industry is increasingly recognizing the potential of psychedelics to treat mental health disorders such as PTSD [2] - The partnership with the consulting firm aims to educate policymakers on the therapeutic potential of psychedelics and support the development of balanced regulations [3]

CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder Vancouver, Canada, June 05, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the enrollment of the first pa ...